Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Add To Watchlist

Recent & Breaking News (NYSEAM:TOVX)

Synthetic Biologics to Report 2020 Second Quarter Operational Highlights and Financial Results on August 6, 2020

PR Newswire July 29, 2020

Synthetic Biologics Announces Submission of IND Application to U.S. FDA for SYN-020 Intestinal Alkaline Phosphatase

PR Newswire June 30, 2020

Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020 to Treat and Prevent Age-Related Metabolic and Inflammatory Diseases

PR Newswire May 27, 2020

Synthetic Biologics Reports 2020 First Quarter Operational Highlights and Financial Results

PR Newswire May 5, 2020

Synthetic Biologics to Report 2020 First Quarter Operational Highlights and Financial Results on May 5, 2020

PR Newswire April 28, 2020

Startup by Silicon Valley Nobel Protege Invents Compact Home Device with Blockchain Technology Capable of Detecting Coronavirus

ACN Newswire March 21, 2020

Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results

PR Newswire February 20, 2020

Synthetic Biologics to Report 2019 Year End Operational Highlights and Financial Results on February 20, 2020

PR Newswire February 13, 2020

Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American

PR Newswire February 7, 2020

Synthetic Biologics to Present at the 2020 BIO CEO & Investor Conference

PR Newswire February 4, 2020

Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients

PR Newswire January 7, 2020

Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan

PR Newswire November 27, 2019

Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results

PR Newswire November 4, 2019

Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019

PR Newswire October 28, 2019

Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

PR Newswire September 26, 2019

Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results

PR Newswire August 8, 2019

Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019

PR Newswire August 1, 2019

Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards

PR Newswire July 1, 2019

Synthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results

PR Newswire May 8, 2019

Synthetic Biologics to Report 2019 First Quarter Operational Highlights and Financial Results on May 8, 2019

PR Newswire April 30, 2019